-
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
-
Seok-Jin Kim, Jiyeon Hyeon, Inju Cho, Young Hyeh Ko, Won Seog Kim
-
Cancer Res Treat. 2019;51(2):611-622. Published online July 20, 2018
-
DOI: https://doi.org/10.4143/crt.2018.191
-
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), realworld data about the efficacy of pembrolizumab in NHL patients are limited.
Materials and methods
We analyzed the outcome of 30 relapsed or refractory NHL patients treated with pembrolizumab, and compared the outcome between Epstein-Barr virus (EBV)‒positive and negative subtypes because EBV infection of tumor cells can upregulate PDL1 expression.
Results
Seven patients with EBV-positive NHL showed a response including NK/T-cell lymphoma (6/14, 44%) and primary mediastinal B-cell lymphoma (1/4, 25%) whereas EBV-negative subtypes did not respond such as diffuse large B-cell lymphoma and T-lymphoblastic lymphoma. We also evaluated PDL1 expression using tumor tissue of 76 patients. High PDL1 expression (positive staining of > 50% of tumor cells) was more frequent in NK/T-cell lymphoma and primary mediastinal B-cell lymphoma than other subtypes. Thus, PDL1 expression was significantly higher in EBV-positive (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001). Furthermore, NK/T-cell lymphoma patients with high PDL1 expression showed a higher response (4/6, 67%) than those with low PDL1 expression (1/5, 20%).
Conclusion
Pembrolizumab could be useful as a salvage treatment for relapsed or refractory EBV-positive NHL, especially NK/T-cell lymphoma. However, its efficacy in EBV-negative NHL with low or absent PDL1 expression is still not clear although pembrolizumab could be a potential treatment option for relapsed or refractory NHL.
-
Citations
Citations to this article as recorded by
- Tislelizumab and Radiation Therapy in Low-Risk Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Phase II Study Protocol
Jia-Ying Li, Shu-Nan Qi, Chen Hu, Xin Liu, Yong Yang, Tao Wu, Rong Zheng, Xiao-Li Feng, Xiao-Guang Ni, Feng-Yan Jin, Yu-Qin Song, Wei-Ping Liu, Sheng-Yu Zhou, Ye-Xiong Li Future Oncology.2024; 20(5): 245. CrossRef - Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A
Literature Review
Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi Current Cancer Therapy Reviews.2024; 20(1): 53. CrossRef - The IPTA Nashville consensus conference on post‐transplant lymphoproliferative disorders after solid organ transplantation in children: IV‐consensus guidelines for the management of post‐transplant lymphoproliferative disorders in children and adolescents
Upton D. Allen, Arnaud G. L'Huillier, Catherine M. Bollard, Thomas G. Gross, Robert J. Hayashi, Britta Höcker, Britta Maecker‐Kolhoff, Stephen D. Marks, George Vincent Mazariegos, Francoise Smets, Ralf U. Trappe, Gary Visner, Richard E. Chinnock, Patrizia Pediatric Transplantation.2024;[Epub] CrossRef - Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee Cancer Research and Treatment.2024; 56(2): 681. CrossRef - Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma
Wendy W. L. Lee, Jing Quan Lim, Tiffany P. L. Tang, Daryl Tan, Ser Mei Koh, Kia Joo Puan, Liang Wei Wang, Jackwee Lim, Kim Peng Tan, Wee Joo Chng, Soon Thye Lim, Choon Kiat Ong, Olaf Rotzschke Frontiers in Immunology.2024;[Epub] CrossRef - Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art
Magda Zanelli, Valentina Fragliasso, Paola Parente, Alessandra Bisagni, Francesca Sanguedolce, Maurizio Zizzo, Giuseppe Broggi, Stefano Ricci, Andrea Palicelli, Moira Foroni, Fabrizio Gozzi, Pietro Gentile, Andrea Morini, Nektarios Koufopoulos, Rosario Ca International Journal of Molecular Sciences.2024; 25(12): 6447. CrossRef - EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo American Journal of Hematology.2024; 99(10): 2002. CrossRef - Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Maryam Pourmaleki, Caitlin J. Jones, Sabrina D. Mellinghoff, Brian D. Greenstein, Priyadarshini Kumar, Miguel Foronda, Daniel A. Navarrete, Carl Campos, Mikhail Roshal, Nikolaus Schultz, Sohrab P. Shah, Andrea Schietinger, Nicholas D. Socci, Travis J. Hol Clinical Cancer Research.2024; 30(17): 3881. CrossRef - PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis
Youli Li, Yonghe Wu, Sufen Cao, Baohua Yu, Qunling Zhang, Zuguang Xia, Junning Cao, Fangfang Lv, Guang-Liang Chen Blood Research.2024;[Epub] CrossRef - A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Zachariah DeFilipp, Alex F. Herrera, David C. Fisher, Ann S. LaCasce, Oreofe O. Odejide, Samuel Y. Ng, Caron A. Jacobson, Reid W. Merryman, Austin I. Kim, Yago L. Ni Blood.2023; 142(7): 621. CrossRef - The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
Yanxia He, Yan Gao, Liqin Ping, Haixia He, Cheng Huang, Bing Bai, Xiaoxiao Wang, Zhiming Li, Qingqing Cai, Yuhua Huang, Xueyi Pan, Wenbin Zeng, Yanan Liu, Huiqiang Huang Journal of Cancer Research and Clinical Oncology.2023; 149(5): 2017. CrossRef - Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment
Chunlan Zhang, Leiming Wang, Caigang Xu, Heng Xu, Yu Wu Frontiers in Pharmacology.2023;[Epub] CrossRef - The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies
Maria G. Desimio, Daniela A. Covino, Beatrice Rivalta, Caterina Cancrini, Margherita Doria Cancers.2023; 15(6): 1914. CrossRef - Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer
Jie Zhou, Guanming Chen, Jiuling Wang, Bo Zhou, Xuemin Sun, Jinsong Wang, Shu Tang, Xiangju Xing, Xiaofei Hu, Yang Zhao, Yu Peng, Wenjiong Shi, Tingting Zhao, Yuzhang Wu, Hanbing Zhong, Ni Hong, Zhihua Ruan, Yi Zhang, Wenfei Jin Oncogenesis.2023;[Epub] CrossRef - Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies
Till Braun, Alexandra Schrader Cancers.2023; 15(9): 2532. CrossRef - Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
Sarah Perdikis-Prati, Semira Sheikh, Antonin Bouroumeau, Noémie Lang Biomedicines.2023; 11(6): 1720. CrossRef - First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study
Xiaoxiao Wang, Lei Wen, Jing Liao, Yanfen Feng, Yuhong Li, Zhaoming Zhou, Cheng Zhou, Huiqiang Huang British Journal of Haematology.2023; 202(4): 812. CrossRef - Advances and challenges of immunotherapies in NK/T cell lymphomas
Ling He, Na Chen, Lei Dai, Xingchen Peng iScience.2023; 26(11): 108192. CrossRef - Adult's Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis: A case report
Yi Sun, Han Yao, Xiaofeng Yu, Yunzhao Chen, Chen Chai Clinical Case Reports.2023;[Epub] CrossRef - Serious consequences of Epstein‐Barr virus infection: Hemophagocytic lymphohistocytosis
Lingyue Xu, Xiaofang Guo, Hongzai Guan International Journal of Laboratory Hematology.2022; 44(1): 74. CrossRef - Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam Diagnostics.2022; 12(2): 409. CrossRef - The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers
Alison Felipe Bordini Biggi, Deilson Elgui de Oliveira Biomolecules.2022; 12(3): 397. CrossRef - Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
Xi Chen, Wanchun Wu, Wenwen Wei, Liqun Zou Frontiers in Pharmacology.2022;[Epub] CrossRef - EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management
Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo American Journal of Hematology.2022; 97(7): 951. CrossRef - Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer Journal of Clinical Medicine.2022; 11(10): 2699. CrossRef - Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders
Susan Swee-Shan Hue, Siok-Bian Ng, Shi Wang, Soo-Yong Tan Cancers.2022; 14(10): 2483. CrossRef - Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han, Wenbin Qian Cancer Communications.2022; 42(6): 493. CrossRef - Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
N Nora Bennani, Hyo Jin Kim, Levi D Pederson, Pamela J Atherton, Ivana N Micallef, Gita Thanarajasingam, Grzegorz S Nowakowski, Thomas Witzig, Andrew L Feldman, Stephen M Ansell Journal for ImmunoTherapy of Cancer.2022; 10(6): e004984. CrossRef - Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma
Felix Marsh-Wakefield, Angela L Ferguson, Ken Liu, Cositha Santhakumar, Geoffrey McCaughan, Umaimainthan Palendira Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef - Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong Seminars in Hematology.2022; 59(4): 198. CrossRef - Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
Seok Jin Kim, Kyung Ju Ryu, Bon Park, Sang Eun Yoon, Junhun Cho, Yoon Park, Won Seog Kim Cancers.2022; 14(22): 5618. CrossRef - Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma
Guang-Liang Chen, Zu-Guang Xia, Jia Jin, Bao-Hua Yu, Junning Cao, Amir Radfar Journal of Oncology.2021; 2021: 1. CrossRef - Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
Lee S. Nguyen, Lisa Raia, Bénédicte Lebrun-Vignes, Joe-Elie Salem Frontiers in Pharmacology.2021;[Epub] CrossRef - Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience
Yang Fu, Yue Zheng, Pei-Pei Wang, Yue-Yun Chen, Zhen-Yu Ding OncoTargets and Therapy.2021; Volume 14: 1073. CrossRef - EBV et immunodépression
Y. Dieudonne, M. Martin, A.-S. Korganow, D. Boutboul, A. Guffroy La Revue de Médecine Interne.2021; 42(12): 832. CrossRef - PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
Joshua W. D. Tobin, Karolina Bednarska, Ashlea Campbell, Colm Keane Cells.2021; 10(5): 1152. CrossRef - NK-/T-cell lymphomas
Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang Leukemia.2021; 35(9): 2460. CrossRef - The role of EBV in haematolymphoid proliferations: emerging concepts relevant to diagnosis and treatment
Emad Ababneh, Anas M Saad, Genevieve M Crane Histopathology.2021; 79(4): 451. CrossRef - Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M. Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E. Brammer, Eric D. Jacobsen, Dok Hyun Yoon, Cheolwon Suh, Felipe Suarez, John Radford, Lihua E. Budde, Jin Seok Kim, Emmanuel Bachy, H Annals of Hematology.2021; 100(10): 2529. CrossRef - The Role of Epstein–Barr virus-encoded Latent Membrane Proteins in Host Immune Escape
Yuanyuan Jiang, Yuan Ding, Shuzhen Liu, Bing Luo Future Virology.2021; 16(8): 565. CrossRef - EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1)
Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, Maurizio Zizzo, Giovanni Martino, Cecilia Caprera, Valentina Fragliasso, Alessandra Soriano, Luca Valle, Stefano Ricci, Alberto Cavazza, Francesco Merli, Stefano A. Pileri, Stefano Ascani Cancers.2021; 13(18): 4578. CrossRef - Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report
Fatemeh Adabifirouzjaei, Bharam Khazai, Ghazaleh Azami, Ghazaleh Shoja-e-Razavi Journal of Medical Case Reports.2021;[Epub] CrossRef - Clinical and Therapeutic Implications of Epstein–Barr Virus in HIV-Related Lymphomas
Miriam Verdu-Bou, Gustavo Tapia, Agueda Hernandez-Rodriguez, Jose-Tomas Navarro Cancers.2021; 13(21): 5534. CrossRef - Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein–Barr Virus
Leila Sawada, Antonio Carlos Rosário Vallinoto, Igor Brasil-Costa Biomolecules.2021; 11(12): 1792. CrossRef - Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
Alejandro Olivares-Hernández, Luis Figuero-Pérez, José Pablo Miramontes-González, Álvaro López-Gutiérrez, Rogelio González-Sarmiento, Juan Jesús Cruz-Hernández, Emilio Fonseca-Sánchez Life.2021; 11(12): 1400. CrossRef - EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk‐stratification and management
Brady E. Beltran, Denisse Castro, Sally Paredes, Roberto N. Miranda, Jorge J. Castillo American Journal of Hematology.2020; 95(4): 435. CrossRef - Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
Junhun Cho, Seok Jin Kim, Woong-Yang Park, Jinho Kim, Jeongmin Woo, Gahyun Kim, Sang Eun Yoon, Young Hyeh Ko, Won Seog Kim Modern Pathology.2020; 33(4): 603. CrossRef - PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jenni Blood Advances.2020; 4(1): 122. CrossRef - Checkmate for EBV-HLH
Nader Kim El-Mallawany, Kenneth L. McClain Blood.2020; 135(11): 782. CrossRef - CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
Yue Song, Wei Song, Zhaoming Li, Wenting Song, Yibo Wen, Jiwei Li, Qingxin Xia, Mingzhi Zhang Frontiers in Oncology.2020;[Epub] CrossRef - Stage IV natural killer/T-cell lymphoma with chronic active Epstein–Barr virus, treated with pembrolizumab and TCRαβ-depleted haploidentical hematopoietic stem cell transplantation
Yeong Eun Kim, Hyery Kim, Juhee Shin, So Yoon Min, Sung Han Kang, Jin Kyung Suh, Kyung-Nam Koh, Ho Joon Im Leukemia & Lymphoma.2020; 61(9): 2250. CrossRef - Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future
Sandhya Sharma, Wingchi K Leung, Helen E Heslop Current Stem Cell Reports.2020; 6(2): 17. CrossRef - The roles of programmed death ligand 1 in virus-associated cancers
Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo Infection, Genetics and Evolution.2020; 84: 104368. CrossRef - Immune-Checkpoint Blockade Therapy in Lymphoma
Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, Yosuke Minami International Journal of Molecular Sciences.2020; 21(15): 5456. CrossRef - Multiplex immunohistochemistry in lymphoma pathology: a research tool for study of the immune microenvironment
Matthew Pugh, Ayse U. Akarka, Kelly Hunter, Stefan Dojcinov, Teresa Marafioti Diagnostic Histopathology.2020; 26(9): 407. CrossRef - Targeting immune checkpoints in hematological malignancies
Basit Salik, Mark J. Smyth, Kyohei Nakamura Journal of Hematology & Oncology.2020;[Epub] CrossRef - Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
Yonggang Pei, Josiah H. Y. Wong, Erle S. Robertson Cancers.2020; 12(9): 2565. CrossRef - Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals
Polina Shindiapina, Elshafa H. Ahmed, Anna Mozhenkova, Tamrat Abebe, Robert A. Baiocchi Frontiers in Oncology.2020;[Epub] CrossRef - Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Ji-Yoon Noh, Huiyun Seo, Jungwoon Lee, Haiyoung Jung International Journal of Molecular Sciences.2020; 21(21): 8000. CrossRef - EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas
Danielle L.V. Maracaja, Vidya Puthenpura, Salley G. Pels, Dennis P. O’Malley, Jeffrey L. Sklar, Karin E. Finberg, Mina L. Xu Applied Immunohistochemistry & Molecular Morphology.2020; 28(10): 725. CrossRef - Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Robert Pytlik, Kamila Polgarova, Jana Karolova, Pavel Klener Vaccines.2020; 8(4): 708. CrossRef - Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
Zheng Yan, Shuna Yao, Yanyan Liu, Jianbo Zhang, Peng Li, Haiying Wang, Junfeng Chu, Shuang Zhao, Zhihua Yao Frontiers in Oncology.2020;[Epub] CrossRef - Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, Junhun Cho, Sang Eun Yoon, Ji Young Lee, Kyung Ju Ryu, Young Hyeh Ko, Youngil Koh, Duck Cho, Soon Thye Lim, Marie Beck Enemark, Francesco D’Amore, Mette Bjerre, Choon Kiat Ong, Won Seog Kim Blood.2020; 136(24): 2754. CrossRef - Pembrolizumab
Reactions Weekly.2019; 1754(1): 273. CrossRef - Immune checkpoint inhibitors in the treatment of virus-associated cancers
Peipei Gao, Cordelle Lazare, Canhui Cao, Yifan Meng, Ping Wu, Wenhua Zhi, Shitong Lin, Juncheng Wei, Xiaoyuan Huang, Ling Xi, Gang Chen, Junbo Hu, Ding Ma, Peng Wu Journal of Hematology & Oncology.2019;[Epub] CrossRef
-
13,341
View
-
618
Download
-
71
Web of Science
-
65
Crossref
-
Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute
-
Yooju Shin, Sang Yun Ha, Jiyeon Hyeon, Boram Lee, Jeeyun Lee, Kee-Taek Jang, Kyoung-Mee Kim, Young Suk Park, Cheol-Keun Park
-
Cancer Res Treat. 2015;47(4):738-746. Published online February 16, 2015
-
DOI: https://doi.org/10.4143/crt.2014.224
-
-
Abstract
PDFPubReaderePub
- Purpose
Management of gastroenteropancreatic (GEP) neuroendocrine tumors with liver metastases (NETLM) presents many clinical challenges. Assessment of the extent of disease and primary tumor site is crucial for management. In this study, we investigated the primary tumor sites and prognostic factors in GEP NETLM among Korean patients. Materials and Methods We reviewed the medical records of 72 Korean patients diagnosed with GEP NETLM between January 1999 and May 2013, focusing on their clinical and pathologic characteristics.
Results The most frequently encountered primary tumor sites were the pancreas (n=25, 35%), stomach (n=8, 11%), gall bladder (n=4, 6%) and rectum (n=3, 4%). Twenty-five patients (35%) had occult primary tumor. Twelve patients (17%) had histological grade G1 tumors, 30 patients (42%) had G2 tumors, and 30 patients (42%) had G3 tumors. The mean follow-up period after histological confirmation of hepatic metastases was 11.30±2.44 months for G3 tumors, 19.67±4.09 months for G2 tumors, and 30.67±6.51 months for G1 tumors. Multivariate analyses revealed that an unknown primary tumor site (p=0.001) and higher histological grade (p < 0.001) were independent prognostic indicators for shorter overall survival (OS). Most long-term survivors (OS > 24 months) had received antitumor treatment. Conclusion The primary tumor site most frequently associated with GEP NETLM was the pancreas. Unknown primary tumor and higher histological grade were independent prognostic indicators for shorter OS. Patients identified as being at a risk of shorter OS should be followed up closely.
-
Citations
Citations to this article as recorded by
- Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database
Abuduhaibaier Sadula, Gang Li, Dianrong Xiu, Chen Ye, Siqian Ren, Xin Guo, Chunhui Yuan, Min Tang Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef - Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors
Xiaoxiao Jiao, Wenqing Luan, Xiaoqian Peng, Lu Liu, Lianfeng Zhang, Lin Zhou Medicine.2020; 99(51): e23655. CrossRef - Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm
Xiao-Ning Kang, Xiao-Yu Zhang, Jie Bai, Zun-Yi Wang, Wen-Jie Yin, Li Li World Journal of Gastrointestinal Oncology.2019; 11(5): 436. CrossRef - Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
Lingaku Lee, Tetsuhide Ito, Robert T Jensen Expert Review of Anticancer Therapy.2019; 19(12): 1029. CrossRef - A Case Report: Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Aggressive Neuroendocrine Component
Quang Duy Pham, Ichiro Mori, Robert Y. Osamura Case Reports in Pathology.2017; 2017: 1. CrossRef - Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series
Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Yuichi Waragai, Mika Takasumi, Satoshi Kawana, Yuko Hashimoto, Takuto Hikichi, Hiromasa Ohira World Journal of Clinical Oncology.2017; 8(3): 293. CrossRef - Gastroenteropancreatic—origin neuroendocrine carcinomas
Yong Gyun Won, Kyung-Jin Seo, Jiyeon Hyeon, Ok Ran Shin, Eundeok Chang, Der Sheng Sun, Hae Sung Won, Yoon Ho Ko, Sae Jung Na, Su Lim Lee, Young Mi Ku, Dong Soo Lee Medicine.2017; 96(49): e9009. CrossRef - A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases
Liangtao Ye, Huilin Ye, Quanbo Zhou, Zhihua Li, Qing Lin, Langping Tan, Wenchao Gao, Zhiqiang Fu, Shangyou Zheng, Rufu Chen International Journal of Surgery.2016; 29: 108. CrossRef - Liver Metastasis of Gastrointestinal Neuroendocrine Tumors: A Single Center Experience
Bita Geramizadeh, Ali Kashkooe, Seyed Ali Malekhosseini Hepatitis Monthly.2016;[Epub] CrossRef - Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification
Deepak Kalyansingh Burad, Thomas Alex Kodiatte, Sayd Mohamed Rajeeb, Ashish Goel, Chundamannil Eapen Eapen, Banumathi Ramakrishna World Journal of Gastroenterology.2016; 22(40): 8956. CrossRef - Unusual endoscopic findings of gastric neuroendocrine tumor
Kazuhiro Kishi, Akihiko Fujisawa, Minoru Horikita, Yoshihiro Nakai, Kazushi Ooshimo, Fumiko Kishi, Masako Kimura, Chun-che Lin, Tetsuji Takayama The Journal of Medical Investigation.2015; 62(3.4): 251. CrossRef
-
11,914
View
-
77
Download
-
11
Web of Science
-
11
Crossref
|